Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Amgen (AMGN) to $275 from $285 and keeps an Equal Weight rating on the shares. The firm notes Amgen’s 2023 guidance underlines base business challenges. Further, Wells thinks Horizon Therapeutics (HZNP) integration and growth thereafter is needed for the stock to work from here.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMGN:
- Amgen price target lowered to $253 from $276 at BMO Capital
- Amgen price target lowered to $289 from $307 at Cowen
- Amgen price target lowered to $220 from $240 at Credit Suisse
- Amgen price target lowered to $230 from $240 at Barclays
- Amgen, Horizon Therapeutics receive second request for additional info from FTC